Immunovant, Inc. (IMVT)
| Market Cap | 1.51B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -99.82M |
| Shares Out | 97.97M |
| EPS (ttm) | -1.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $15.42 |
| Previous Close | $15.88 |
| Change ($) | -0.46 |
| Change (%) | -2.90% |
| Day's Open | 15.90 |
| Day's Range | 15.25 - 16.08 |
| Day's Volume | 567,913 |
| 52-Week Range | 11.80 - 53.75 |
New York, New York--(Newsfile Corp. - April 18, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Immunovant, Inc. ("Immunovant" or "the Co...
New York, New York--(Newsfile Corp. - April 16, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securi...
New York, New York--(Newsfile Corp. - April 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...
Atlanta, Georgia--(Newsfile Corp. - April 16, 2021) - Holzer & Holzer, LLC reminds investors who suffered financial losses on purchases of Immunovant, Inc. ("Immunovant" or the "Company") (NASDAQ: IMVT)...
(Newsfile Corp. - April 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immunovant, Inc. ("Immunovant" or "the Company...
New York, New York--(Newsfile Corp. - April 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...
LOS ANGELES--(BUSINESS WIRE)---- $IMVT #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. (IMVT)
Los Angeles, California--(Newsfile Corp. - April 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immunovant, Inc. ("Im...
New York, New York--(Newsfile Corp. - April 14, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...
New York, New York--(Newsfile Corp. - April 14, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Immunovant, Inc. ("Immunovant" or "the Co...
New York, New York--(Newsfile Corp. - April 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...
Los Angeles, California--(Newsfile Corp. - April 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immunovant, Inc. ("Im...
New York, New York--(Newsfile Corp. - April 9, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Immu...
New York, New York--(Newsfile Corp. - April 9, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securit...
New York, New York--(Newsfile Corp. - April 7, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securit...
New York, New York--(Newsfile Corp. - April 7, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Immu...
Los Angeles, California--(Newsfile Corp. - April 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immunovant, Inc. ("Imm...
New York, New York--(Newsfile Corp. - April 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Immu...
Los Angeles, California--(Newsfile Corp. - April 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (N...
NEW YORK, April 1, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", ...
New York, New York--(Newsfile Corp. - March 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...
New York, New York--(Newsfile Corp. - March 25, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?
Los Angeles, California--(Newsfile Corp. - March 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (...
NEW YORK, March 18, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class acti...
LOS ANGELES, March 17, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. ("Immunovant" or...
Los Angeles, California--(Newsfile Corp. - March 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (...
Los Angeles, California--(Newsfile Corp. - March 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (...
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant",...
New York, New York--(Newsfile Corp. - March 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...
Los Angeles, California--(Newsfile Corp. - March 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (...
Los Angeles, California--(Newsfile Corp. - March 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (...
NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporati...
Immunovant (IMVT) gains following Roivant's announcement of a possible buyout of the company. Roivant is a major stakeholder of Immunovant.
Los Angeles, California--(Newsfile Corp. - March 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (N...
New York, New York--(Newsfile Corp. - March 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Immu...
Immunovant, Inc. (NASDAQ: IMVT), Anchiano Therapeutics Ltd. (NASDAQ: ANCN) and OpGen, Inc. (NASDAQ: OPGN) are among the biggest healthcare gainers on Monday.
The company could get a buyout offer soon.
NEW YORK, March 07, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class ...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, ...
NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corpo...
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Immunovant, Inc. ("Immunovant" or "the Company")...
New York, New York--(Newsfile Corp. - March 4, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Immunovant, Inc. ("Immunovant" or "the Com...
NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Immunovan...
BENSALEM, Pa.--(BUSINESS WIRE)---- $IMVT #CLASSACTION--Law Offices of Howard G. Smith reminds investors of the upcoming April 20, 2021 deadline to file a lead plaintiff motion in the case filed on behal...
NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", ...
Los Angeles, California--(Newsfile Corp. - March 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (N...
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class ...
LOS ANGELES--(BUSINESS WIRE)---- $IMVT #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 20, 2021 deadline to file a lead plaintiff motion in the class action fil...
About IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New... [Read more...]
| Industry Biotechnology | |
| Stock Exchange NASDAQ | Ticker Symbol IMVT |
Analyst Forecasts
According to 11 analysts, the average rating for Immunovant stock is "Strong Buy." The 12-month stock price forecast is 39.10, which is an increase of 153.57% from the latest price.